OBJECTIVES/HYPOTHESIS: 1) To clarify essential voice tremor (EVT) phenomenology; 2) To report a management paradigm for essential voice tremor using botulinum toxin. STUDY DESIGN: Retrospective analysis of prospectively collected data. METHODS: Phenomenology from patients diagnosed with EVT between April 1996 and March 2012 was recorded, charted, and analyzed. A paradigm for treatment of EVT using botulinum toxin based on individualized clinical findings is discussed. RESULTS: Sixteen patients were included. Fewer than 50% patients were responsive to centrally acting oral medications. Fifteen patients analyzed had horizontal laryngeal tremor and received botulinum toxin injections to bilateral thyroarytenoid muscles. Thirteen patients had a vertical laryngeal tremor, and these patients underwent additional strap muscle injections. All patients had symptomatic improvement with reduced tremor amplitude. Dose adjustments over time depended on degree of symptomatic improvement. CONCLUSIONS: Management of essential voice tremor with botulinum toxin is optimized by individualizing treatment based on the tremor phenomenology observed during clinical examination. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: 1) To clarify essential voice tremor (EVT) phenomenology; 2) To report a management paradigm for essential voice tremor using botulinum toxin. STUDY DESIGN: Retrospective analysis of prospectively collected data. METHODS: Phenomenology from patients diagnosed with EVT between April 1996 and March 2012 was recorded, charted, and analyzed. A paradigm for treatment of EVT using botulinum toxin based on individualized clinical findings is discussed. RESULTS: Sixteen patients were included. Fewer than 50% patients were responsive to centrally acting oral medications. Fifteen patients analyzed had horizontal laryngeal tremor and received botulinum toxin injections to bilateral thyroarytenoid muscles. Thirteen patients had a vertical laryngeal tremor, and these patients underwent additional strap muscle injections. All patients had symptomatic improvement with reduced tremor amplitude. Dose adjustments over time depended on degree of symptomatic improvement. CONCLUSIONS: Management of essential voice tremor with botulinum toxin is optimized by individualizing treatment based on the tremor phenomenology observed during clinical examination. LEVEL OF EVIDENCE: 4.
Authors: Priyesh N Patel; Edmond K Kabagambe; Jennifer C Starkweather; Matthew Keller; Vahram Gamsarian; Jane Lee; Vishnutheert Kulkarni; C Gaelyn Garrett; David O Francis Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-04-01 Impact factor: 6.223
Authors: Priyesh N Patel; Edmond K Kabagambe; Jennifer C Starkweather; Matthew Keller; Zaki A Ahmed; Simone C Gruber; Jordan S Akins; C Gaelyn Garrett; David O Francis Journal: Laryngoscope Date: 2018-11-13 Impact factor: 3.325
Authors: Natalie Justicz; Edie R Hapner; Joshua S Josephs; Benjamin C Boone; Hyder A Jinnah; Michael M Johns Journal: Laryngoscope Date: 2015-07-21 Impact factor: 3.325